Description
Authoritative market research on cell therapy, gene therapy, and RNA therapy analyzing markets by disease type
Cell therapy and gene therapy represent a frontier in modern medicine, promising revolutionary treatments by treating the underlying genetic causes of disease and by genetically controlling the body’s immune system. Recent years have seen an increase in new therapies and the pipeline indicates this trend will continue. A large range of therapeutic areas from oncology to cardiology have seen rapidly proliferating clinical trials. Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029 from Kalorama Information presents the market in segments that cover market estimates and forecasts, the development pipeline, and the competitive landscape of leading providers for each therapeutic area.
The report examines global developments in cell, gene, and RNA therapy markets for the select diseases and conditions in respective chapters, including principal products, trends in research and development, market breakdown of therapies, regional market revenues summary, and competitor summary.
The following therapeutic areas are covered in individual chapters with accompanying tables and figures:
- Oncology
- Neurology
- Musculoskeletal
- Dermatology
- Cardiology/non-oncology blood
- Other
Scope
The report covers markets for cell therapies, gene therapies, and other various forms of RNA therapies. This report does not include RNA therapies for COVID-19 or mRNA vaccines for infectious diseases in its scope.
We are excluding mRNA-based products for infectious disease in this report because that area has largely been related to vaccines which is distinct; and partly due to the obscurity of the definition of cell and gene therapy. It will, however, be addressed in other Kalorama Information vaccine reports. RNA, antisense, and related types of therapies for other diseases are included due to the broad definition of gene therapy, including the use of nucleic acids to influence gene expression.
Note that this report also does not focus on cord blood products in the scope; these have technically been approved as cell therapy products by the FDA. There is some debate as to whether these are more akin to transplants.
Diseases are categorized into therapeutic areas primarily according to the general consensus but this is often an over-simplification; genetic diseases can become complicated to classify due to many systems being affected. In some cases, there may be inconsistencies. For example, a genetic mutation may affect the liver which results in excessive amounts of a certain molecule. This molecule then causes harm to the brain, and the condition is categorized as neurological despite the origin being in the liver.
Generally, the primary effects will first dictate the category, in combination with the condition’s cause. It can be case-by-case.
Information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company reports and literature; government documents and databases; research journals and reports; and general medical and business journals. Primary research methods include telephone interviews and email correspondence with company representatives, researchers and physicians. These interviews were conducted with the purpose of capturing the perspectives from industry participants on the market opportunity and current trends. This was the basis of the formulation of forecasting models and for confirming early findings related to market potential.
The market segments provide highlights and overviews of therapies, market estimates and forecasts, and competitive situations of leading providers. The report also includes information on cell and gene therapies in development and the impact these are expected to have on the market. Throughout the report, several market indicators, trends, and barriers are discussed.
Because gene therapies are currently not available in any wide capacity, there is little precedent upon which to base forecasts. Dollar figures represent the estimated global market for 2023 and expected market for 2029. Forecasts are provided through 2029 ,and the size of each market segment refers to manufacturers’ revenues.
Table of Contents
Chapter 1: Executive Summary
Overview
Scope and Methodology
Market Overview and Potential
- Figure 1-1: Global Cell and Gene Therapy Market, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
- Table 1-1: Global Cell and Gene Therapy Market, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
Chapter 2: Introduction to Cell and Gene Therapy
Introduction
- Table 2-1: Total Numbers of Approved Cell, Gene, & RNA Therapies, by Type, Q4 2022-Q1 2024 (ending March 2024), Global (count, %)
- Figure 2-1: Share of Total Global Numbers of Approved Cell, Gene, & RNA Therapies, by Type, March 2024 (%)
Cell Therapy
- CAR T
- Stem Cells
- Adult Stem Cells
- Human Embryonic Stem Cells
- Table 2-2: Adult vs. Embryonic Stem Cells
Gene Therapy
- Table 2-3: Somatic vs. Germ Line Gene Therapy
Viral Vector System and New Developments
- Table 2-4: Selected Examples of Viruses in Gene Therapy
- Figure 2-2: Estimated Viral Vector Use in Commercialized Cell and Gene Therapies, by Type, 2022 (%)
Non-viral Systems for Transporting Genes
Gene Editing
Cell and Gene Therapy: Characteristics
- Table 2-5: Cell Therapy vs Gene Therapy
Staffing
Manufacturing Process for CAR-T
Leukapheresis
Activation
Transduction
Expansion
Cell and Gene Therapy Manufacturing Processes
- Table 2-6: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
- Figure 2-3: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
Cost
Reimbursement
Logistics
Mergers and Acquisitions
- Table 2-7: Selected Company Mergers and Acquisitions in the Cell and Gene Therapy Market
Deals, Agreements, and Collaborations
Regulatory Developments
Fast Track
Orphan Drug
Breakthrough Therapy
Accelerated Approval
Priority Review
- Table 2-8: Regulatory Actions and Guidelines for Cell and Gene Therapy, by Select Country
Individualized Gene Therapy Approval Process
Pipeline, Development Overview
Pipeline, Development Progress
- Table 2-9: Global Cell, Gene, & RNA Therapy Clinical Trial Growth (pre-clinical I through phase III), Q4 2022-Q1 2024 ($ millions, %)
- Figure 2-4: Global Cell, Gene, & RNA Therapy Development Progress (pre-clinical through phase III), as of March 2024
- Table 2-10: Global Gene Therapy Pipeline, by Phase, Q4 ’22-Q1 ’24 (count, %)
- Figure 2-5: Global Gene Therapy Pipeline Shares by Phase, Q1 ’24 (%)
Pipeline by Condition and Therapeutic Area
- Table 2-11: Global Cell, Gene, & RNA Therapy Pipeline, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous, Other), Q4 ’22-Q1 ’24 (count, %)
- Figure 2-6: Global Gene Therapy Pipeline Shares, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous), Q1 ’24 (%)
- Table 2-12: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous), Q4 ’22-Q1 ’24 (count, %)
- Table 2-13: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Rare Disease (Amyotrophic lateral sclerosis; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, leukemia, chronic lymphocytic; Cancer, liver; Cancer, lymphoma, B-cell; Cancer, lymphoma, B-cell, diffuse large; Cancer, lymphoma, non-Hodgkin’s; Cancer, lymphoma, T-cell; Cancer, mesothelioma; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Cystic fibrosis; Dystrophy, Duchenne’s muscular; Hemophilia A; Hemophilia B; Retinitis pigmentosa; Other), Q4 ’22-Q1 ’24 (count, %)
- Figure 2-7: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Rare Disease (Amyotrophic lateral sclerosis; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, leukemia, chronic lymphocytic; Cancer, liver; Cancer, lymphoma, B-cell; Cancer, lymphoma, B-cell, diffuse large; Cancer, lymphoma, non-Hodgkin’s; Cancer, lymphoma, T-cell; Cancer, mesothelioma; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Cystic fibrosis; Dystrophy, Duchenne’s muscular; Hemophilia A; Hemophilia B; Retinitis pigmentosa), Q4 ’22-Q1 ’24 (%)
- Table 2-14: Global Non-GM Cell Therapy Pipeline, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous), Q4 ’22-Q1 ’24 (count, %)
- Table 2-15: Global Non-GM Cell Therapy Pipeline, by Condition/Disease (Alzheimer’s disease; Arthritis, osteo; Cancer, brain; Cancer, breast; Cancer, leukemia, acute myelogenous; Cancer, liver; Cancer, lung, non-small cell; Cancer, melanoma; Cancer, ovarian; Cancer, solid, unspecified; Cancer, unspecified; COVID-19 complications; Diabetes, Type 1; Graft-versus-host disease; Heart failure; Hepatic dysfunction, unspecified; Infarction, myocardial; Ischemia, cerebral; Parkinson’s disease; Respiratory distress syndrome, acute; Spinal cord injury), Q4 ’22-Q1 ’24 (count, %)
- Table 2-16: Global Non-GM Cell Therapy Pipeline, by Rare Disease Targeted (Amyotrophic lateral sclerosis; Anal fistula; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, liver; Cancer, lymphoma, non-Hodgkin’s; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Dystrophy, Duchenne’s muscular; Epidermolysis bullosa; Fibrosis, pulmonary, idiopathic; Graft-versus-host disease; Huntington’s disease; Myelodysplastic syndrome; Respiratory distress syndrome, acute; Retinitis pigmentosa; Spinal cord injury; Thalassemia), Q4 ’22-Q1 ’24 (count, %)
- Table 2-17: Global RNA Therapy Pipeline, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Antiparasitic, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous), Q4 ’22-Q1 ’24 (count, %)
- Table 2-18: Global RNA Therapy Pipeline, by Rare Disease Targeted (Amyotrophic lateral sclerosis; Cancer, liver; Cancer, ovarian; Cancer, pancreatic; Cystic fibrosis; Dementia, frontotemporal; Dystrophy, Duchenne’s muscular; Dystrophy, myotonic muscular; Fibrosis, pulmonary, idiopathic; Huntington’s disease; Infection, malaria prophylaxis; Infection, rabies prophylaxis; Primary ciliary dyskinesia; Respiratory distress syndrome, acute), Q4 ’22-Q1 ’24 (count, %)
Phase III Development
- Table 2-19: Phase III Development – Cell and Gene Therapies, Select Projects
End Users
Hospitals
Research Institutes
Wound Care Centers
Cancer Centers
Chapter 3: Cell and Gene Therapy Markets in Oncology
Overview
Biochemistry of Cancer Cells
Causes of Cancer Growth
Environmental Factors, DNA, RNA
- Table 3-1: Virus Association with Human Cancer
Cellular Oncogenes
Tumor Suppressor Genes
Global Cancer Burden
- Figure 3-1: Estimated Number of New Cancer Cases from 2020 to 2040, Both Sexes, Age 0-85+, All Cancers
- Figure 3-2: Incidence of Cancer, by Type (Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Oesophagus, Prostate, Stomach, Thyroid), 2020
- Figure 3-3: Worldwide Distribution of Cancer Incidence, by Type (Brest, Cervix Uteri, Colorectum, Liver, Lung, Prostate, Stomach, Other Cancers), 2020
Market Outlook
- Table 3-2: Cell, Gene, & RNA Therapy Markets in Oncology, 2023-2029 ($ millions)
- Figure 3-4: Cell, Gene, & RNA Therapy Markets in Oncology, 2023-2029 ($ millions)
Principal Products
Abecma
APCeden
Breyanzi
Carvykti
CreaVax-RCC
Delytact
Gendicine
Imlygic
Immuncell-LC
Kymriah
Provenge
Tecartus
Yescarta
- Table 3-3: Cell and Gene Therapy in Oncology
Trends in Research and Development
Phase III Development
- Table 3-4: Select Oncology Phase III Cell, Gene, & RNA Therapy Developments, through March 2024
Market Breakdown of Cell and Gene Therapies
- Table 3-5: Oncology Cell and Gene Therapy Markets, by Product Type (CAR-T, Cell Immunotherapy, Gene Therapy), Estimated 2023 and Projected 2029 ($ millions)
- Figure 3-5: Oncology Cell and Gene Therapy Market Distribution, by Product Type (CAR-T, Cell Immunotherapy, Gene Therapy), 2023 (%)
Oncology Cell and Gene Therapy Market by Cancer Type
- Table 3-6: Oncology Cell, Gene, & RNA Therapy Market, by Cancer Type (Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Undefined Blood Cancer, Other Cancers), Estimated 2023 and Projected 2029 ($ millions)
- Table 3-7: Oncology Cell, Gene, & RNA Therapy Market, by General Indication (Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Other Cancers), 2023 (%)
- Figure 3-6: Oncology Cell, Gene, & RNA Therapy Market, by General Indication (Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Other Cancers), 2023 (%)
Regional Market Summary
- Table 3-8: Oncology Cell and Gene Therapy Market, by Country/Region (Europe, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)
- Figure 3-7: Oncology Cell and Gene Therapy Market Summary, by Geographic Region (Europe, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)
Competitor Summary
- Table 3-9: Oncology Cell, Gene, & RNA Therapy Competitor Market Share, Reported and Estimated 2023 ($ millions)
- Figure: 3-8: Oncology Cell, Gene, & RNA Therapy Competitor Market Share, Estimated 2023 (%)
Chapter 4: Cell and Gene Therapy Markets in Neurological-Related Disorders
Overview
Market Outlook
- Table 4-1: Cell, Gene, and RNA Therapies in Neurological-Related Conditions, 2023-2029 ($ millions)
- Figure 4-1: Cell, Gene, and RNA Therapies in Neurological-Related Conditions, 2023-2029 ($ millions)
Principal Products
Amvuttra
Libmeldy/ Lenmeldy
NeuroNata-R
Onpattro
SKYSONA
Spinraza
Stemirac
Wainua
Zolgensma
- Table 4-2: Cell, Gene, and RNA Therapy in Neurological Diseases and Disorders
Trends in Research and Development
Phase III Development
- Table 4-3: Select Neurological Phase III Cell and Gene Therapy Developments, through March 2024
Market Breakdown of Cell and Gene Therapies
- Table 4-4: Neurological Conditions Cell and Gene Therapy Markets, by Product Type (Cell Therapy, Gene Therapy, RNA/Antisense Therapy), Estimated 2023 and Projected 2029 ($ millions)
- Figure 4-2: Neurological Conditions Cell, Gene, & RNA Therapy Market Distribution, by Product Type, 2023 (%)
Regional Market Summary
- Table 4-5: Neurological Conditions Cell and Gene Therapy Market, by Country/Region (Europe, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)
- Figure 4-3: Neurological Conditions Cell, Gene, & RNA Therapy Market Summary, by Geographic Region (Europe, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)
Competitor Summary
- Table 4-6: Neurological Conditions Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2023 ($ millions)
- Figure 4-4: Neurological Conditions Cell, Gene, & RNA Therapy Market Shares, by Company, Estimated 2023 ($ millions)
Chapter 5: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders
Overview
Market Outlook
- Table 5-1: Cell, Gene, & RNA Therapy Markets in Musculoskeletal Conditions and Disorders, 2023-2029 ($ millions)
- Figure 5-1: Cell, Gene, & RNA Therapy Markets in Musculoskeletal Conditions and Disorders, 2023-2029 ($ millions)
Principal Products
AlloStem
Amondys
BIO4
Carticel
Cartiform
CartiLife
Cartistem
Chondron
Elevidys
Exondys
JACC
MACI
Ortho-ACI and Ortho-ATI
Ossron
Osteocel and Osteoplus
Spherox
Trinity Elite and Trinity Evolution
Vyondys
- Table 5-2: Cell and Gene Therapies in Musculoskeletal Diseases and Disorders
Trends in Research and Development
Phase III Development
- Table 5-3: Select Musculoskeletal Phase III Cell and Gene Therapy Developments, through March 2024
Market Breakdown of Cell and Gene Therapies
- Table 5-4: Musculoskeletal Cell, Gene, & RNA Therapy Markets, by Product Type, Estimated 2023 and Projected 2029 ($ millions)
Musculoskeletal Cell and Gene Therapy Market by Indication
- Table 5-5: Musculoskeletal Cell, Gene, & RNA Therapy Market, by General Indication (Bone Defect/Damage Repair, Cartilage Defect/Damage Repair, DMD, Others [Tendon Damage, Osteoarthritis]), Estimated 2023 and Projected 2029 ($ millions)
- Figure 5-2: Musculoskeletal Cell, Gene, & RNA Therapy Market, by General Indication (Bone Defect/Damage Repair, Cartilage Defect/Damage Repair, DMD, Others [Tendon Damage, Osteoarthritis]), Estimated 2023 (%)
Regional Market Summary
- Figure 5-3: Musculoskeletal Cell, Gene, & RNA Therapy Market, by Country/Region (Europe, United States, South Korea, ROW), Estimated 2023 (%)
- Table 5-6: Musculoskeletal Cell, Gene, & RNA Therapy Market, by Country/Region (Europe, United States, South Korea, ROW), Estimated 2023 and Projected 2029 ($ millions)
- Figure: 5-4: Musculoskeletal Cell and Gene Therapy Market Summary, by Geographic Region (Europe, United States, South Korea, ROW), Estimated 2023 and Projected 2029 ($ millions)
Competitor Summary
- Table 5-7: Musculoskeletal Cell, Gene, & RNA Therapy Competitor Market Share, Reported and Estimated 2023 ($ millions)
- Figure 5-5: Musculoskeletal Cell, Gene, & RNA Therapy Market Shares, by Company, Estimated 2023 (%)
Chapter 6: Cell and Gene Therapy Markets in Dermatology
Overview
- Table 6-1: Wound Prevalence, by Type (Skin Ulcers: Pressure Injuries, Venous Statis Ulcers, Diabetic Ulcers and Burns: Outpatient Burns, Hospitalized Burns, and Medically Treated Burns)
Market Outlook
- Figure 6-1: Cell and Gene Therapy Markets in Dermatology, 2023-2029 ($ millions)
Principal Products
Adipocel
Apligraf
CureSkin
Dermagraft
Epicel
Grafix
Holoderm
Kaloderm
KeraHeal/KeraHeal-Allo
LaViv
Orcel
Quencell
RECELL
Rosmir
Stempeutics/Cutisera
StrataGraft
Stravix
TransCyte
Vyjuvek
- Table 6-2: Cell and Gene Therapy in Dermatological Diseases and Disorders
Trends in Research and Development
Phase III Development
- Table 6-3: Select Dermatology Phase III Cell and Gene Therapy Developments, through March 2024
Market Breakdown of Cell and Gene Therapies
- Table 6-4: Dermatology Cell and Gene Therapy Markets, by Product Type (Stem Cells, Skin Cells, Gene/Gene-Modified Cell Therapy), Estimated 2023 and Projected 2029 ($ millions)
- Figure 6-2: Dermatology Cell and Gene Therapy Market Distribution, by Product Type (Stem Cells, Skin Cells, Gene/Gene-Modified Cell Therapy), 2023 (%)
Dermatology Cell and Gene Therapy Market by Indication
Regional Market Summary
- Table 6-5: Dermatology Cell and Gene Therapy Market, by Country/Region (Asia, Europe, United States, Other Countries), Estimated 2023, Projected 2029 ($ millions)
- Figure: 6-3: Dermatology Cell and Gene Therapy Market Summary, by Geographic Region (Asia, Europe, United States, ROW), Estimated 2023 and Projected 2029 ($ millions)
Competitor Summary
- Table 6-6: Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2023 ($ millions)
- Figure: 6-4: Dermatology Cell and Gene Therapy Market Share, by Company, Estimated 2023 (%)
Chapter 7: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders
Overview
Cardiovascular Disease
Selected Blood Disorders
Market Outlook
- Table 7-1: Cell, Gene, and RNA Therapy Markets in Cardiovascular and Blood Disorders, 2023-2029 ($ millions)
- Figure 7-1: Cell, Gene, and RNA Therapy Markets in Cardiovascular and Blood Disorders, 2023-2029 ($ millions)
Principal Products
Collategene
Hearticellgram
HeartSheet
Leqvio
Neovasculgen
Stempeucel
Zynteglo
- Table 7-2: Selected Cell and Gene Therapy in Cardiovascular and Blood Disorders
Phase III Development
- Table 7-3: Select Cardiovascular and Blood Disorder Phase III Cell and Gene Therapy Developments, through Mar 2023
Market Breakdown of Cell, Gene, and RNA Therapies
- Table 7-4: Cardiovascular and Blood Disorders Cell, Gene, & RNA Therapy Markets, by Product Type (Cell-based Gene Therapy, Non-GM Cell, RNA, Other Gene Therapies), Estimated 2023 and Projected 2029 ($ millions)
- Figure 7-2: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Distribution, by Product Type (Cell-based Gene Therapy, Non-GM Cell, RNA, Other Gene Therapies), 2023 (%)
Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication
- Table 7-5: Cardiovascular and Blood Disorders Cell and Gene Therapy Market, by General Indication (Blood, Cardiac, Hypercholesterolemia, Vascular), Estimated 2023 and Projected 2029 ($ millions)
Regional Market Summary
- Table 7-6: Cardiovascular and Blood Disorders Cell and Gene Therapy Market, by Country/Region (APAC, Europe, United States, ROW), Estimated 2023 and Projected 2029 ($ millions)
- Figure 7-3: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary, by Geographic Region (APAC, Europe, United States, ROW), Estimated 2023 and Projected 2029 ($ millions)
Competitor Summary
Chapter 8: Cell and Gene Therapy Markets in Other Conditions
Overview
Market Outlook
- Figure 8-1: Cell and Gene Therapy Markets in Other Conditions, 2023-2029 ($ millions)
- Table 8-1: Cell and Gene Therapy Markets in Other Conditions, 2023-2029 ($ millions)
Principal Products
Alofisel
Cupistem
Givlaari
Glybera
Holoclar
Luxturna
Oxlumo
Rethymic
Strimvelis
Temcell/Prochymal/Ryoncil
- Table 8-2: Cell and Gene Therapy in Other Diseases and Disorders
Trends in Research and Development
Market Breakdown of Cell and Gene Therapies
- Table 8-3: Other Conditions Cell and Gene Therapy Markets, by Product Type (Cell-based Gene Therapy; RNA, Antisense Etc; Stem Cell & Other Cell Therapy; Other Gene Therapy), Estimated 2023 and Projected 2029 ($ millions)
- Figure 8-2: Other Conditions Cell and Gene Therapy Market Distribution, by Product Type (Cell-based Gene Therapy; RNA, Antisense Etc; Stem Cell & Other Cell Therapy; Other Gene Therapy), 2023 (%)
Regional Market Summary
- Table 8-4: Other Conditions Cell and Gene Therapy Market, by Country/Region (Europe, Japan, South Korea, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)
- Figure 8-3: Other Conditions Cell and Gene Therapy Market Summary, by Geographic Region (Europe, Japan, South Korea, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)
Competitor Summary
Chapter 9: Cell and Gene Therapy Market Review
Market Influences
Global Demographics
- Table 9-1: Global Population, through 2050 (population in millions)
- Aging Population
- Figure 9-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
Cost Containment
- Table 9-2: Cost Comparisons for Selected Commercialized Cell and Gene Therapies
Cell and Gene Therapy and Viral Vector Shortages
Global Market Summary
- Table 9-3: Cell, Gene, and RNA Therapy Market Summary, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
- Figure 9-2: Cell, Gene, and RNA Therapy Market Summary, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
- Figure 9-3: Cell and Gene Therapy Market, Distribution of Sales, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023
Cell vs. Gene Therapy Markets
- Table 9-4: Cell, Gene, & RNA Therapy Market Summary, by Method (Gene/CBG Therapy, RNA Therapy, Non-GM Cell Therapy), 2023-2029 ($ millions)
- Figure 9-4: Cell, Gene, & RNA Therapy Market, Distribution of Sales, by Method (Gene/CBG Therapy, RNA Therapy, Non-GM Cell Therapy), 2023 (%)
Regional Market Overview
- Table 9-5: Cell, Gene, & RNA Therapy Market Summary, by Geographical Region (Europe, United States, Other Countries), 2023-2029 ($ millions)
United States
- Table 9-6: Cell, Gene, & RNA Therapy Market Summary for United States, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
- Figure 9-5: U.S. Cell and Gene Therapy Market, Distribution, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023 (%)
- Table 9-7: Major Cell and Gene Therapy Product Approvals, FDA
Europe/European Union
- Table 9-8: Cell, Gene, & RNA Therapy Market Summary for Europe/European Union, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
- Figure 9-6: Europe Cell and Gene Therapy Market Distribution, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023 (%)
- Table 9-9: Major Cell and Gene Therapy Approvals by EMA
Other Countries
- Table 9-10: Cell, Gene, & RNA Therapy Market Summary for Other Countries, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
- Figure 9-7: ROW Cell, Gene, & RNA Therapy Market Distribution, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023 (%)
- Table 9-11: Select Major Cell and Gene Therapy Approvals by Various Regulatory Authorities
Competitor Ranking in Cell and Gene Therapy Markets
- Table 9-12: Estimated Cell and Gene Therapy Sales by Leading Competitor, 2023 Sales ($ millions)
- Figure 9-8: Cell and Gene Therapy Market Share Estimates, 2023
Chapter 10: Market Participants
Leading Influencers
AlloSource
- Table 10-1: AlloSource Corporate Summary
Company Summary
Products
Alnylam Pharmaceuticals, Inc.
- Table 10-2: Alnylam Pharmaceuticals Corporate Summary
Company Summary
Products
Amgen
- Table 10-3: Amgen Corporate Summary
Company Summary
Products
AnGes Inc.
- Table 10-4: AnGes Corporate Summary
Company Summary
Products
Anterogen Co Ltd.
- Table 10-5: Anterogen Corporate Summary
Company Summary
Products
Atara Biotherapeutics
- Table 10-6: Atara Biotherapeutics Corporate Summary
Company Summary
Products
Athersys, Inc
- Table 10-7: Athersys Corporate Summary
Company Summary
Products
BioCardia
- Table 10-8: BioCardia Summary
Company Summary
Products
Biogen, Inc.
- Table 10-9: Biogen Corporate Summary
Company Summary
Products
BioMarin Pharmaceuticals
- Table 10-10: BioMarin Pharmaceuticals Corporate Summary
Company Summary
Products
bluebird bio, Inc.
- Table 10-11: bluebird bio Corporate Summary
Company Summary
Products
BrainStorm Cell Therapeutics
- Table 10-12: BrainStorm Cell Therapeutics Corporate Summary
Company Summary
Products
Bristol-Myers Squibb
- Table 10-13: Bristol-Myers Squibb Corporate Summary
Company Summary
Products
Candel Therapeutics
- Table 10-14: Candel Therapeutics Corporate Summary
Company Summary
Products
Castle Creek Biosciences
- Table 10-15: Castle Creek Corporate Summary
Company Summary
Products
Celyad Oncology
- Table 10-16: Celyad Oncology Corporate Summary
Company Summary
Products
Cook Myosite, Inc
- Table 10-17: Cook Myosite Corporate Summary
Company Summary
Products
Dendreon Pharmaceuticals (Sanpower)
- Table 10-18: Dendreon Corporate Summary
Company Summary
Products
FerGene, Inc (Ferring Pharmaceuticals)
- Table 10-19: FerGene Corporate Summary
Company Summary
Products
Gamida Cell Ltd.
- Table 10-20: Gamida Cell Corporate Summary
Company Summary
Products
GenSight Biologics S.A.
- Table 10-21: GenSight Biologics Corporate Summary
Company Summary
Products
Gilead Sciences, Inc.
- Table 10-22: Gilead Sciences Corporate Summary
Company Summary
Products
Gradalis, Inc
- Table 10-23: Gradalis Corporate Summary
Company Summary
Products
Helixmith
- Table 10-24: Helixmith Corporate Summary
Company Summary
Products
Inovio Pharmaceuticals, Inc.
- Table 10-25: Inovio Pharmaceuticals Corporate Summary
Company Summary
Products
Kiadis Pharma B.V. (Sanofi)
- Table 10-26: Kiadis Pharma Corporate Summary
Company Summary
Products
Medeor Therapeutics
- Table 10-27: Medeor Therapeutics Corporate Summary
Company Summary
Products
MEDIPOST Co, Ltd.
- Table 10-28: MEDIPOST Corporate Summary
Company Summary
Products
MeiraGTx
- Table 10-29: MeiraGTxCorporate Summary
Company Summary
Products
Mesoblast Ltd.
- Table 10-30: Mesoblast Corporate Summary
Company Summary
Products
Northwest Biotherapeutics, Inc.
- Table 10-31: Northwest Biotherapeutics Corporate Summary
Company Summary
Products
Novartis AG
- Table 10-32: Novartis Corporate Summary
Company Summary
Products
NuVasive Biologics
- Table 10-33: NuVasive Biologics Corporate Summary
Company Summary
Products
Orchard Therapeutics
- Table 10-34: Orchard Therapeutics Corporate Summary
Company Summary
Products
Organogenesis
- Table 10-35: Organogenesis Corporate Summary
Company Summary
Products
Orthofix
- Table 10-36: Orthofix Corporate Summary
Company Summary
Products
Osiris Therapeutics, Inc. (part of Smith & Nephew)
- Table 10-37: Osiris Corporate Summary
Company Summary
Products
Pharmicell
- Table 10-38: Pharmicell Corporate Summary
Company Summary
Products
Pluristem Therapeutics, Inc.
- Table 10-39: Pluristem Therapeutics Corporate Summary
Company Summary
Products
Sangamo Therapeutics
- Table 10-40: Sangamo Therapeutics Corporate Summary
Company Summary
Products
Sanofi
- Table 10-41: Sanofi Corporate Summary
Company Summary
Products
Sarepta
- Table 10-42: Sarepta Corporate Summary
Company Summary
Products
Sotio a.s.
- Table 10-43: Sotio Corporate Summary
Company Summary
Products
Spark Therapeutics
- Table 10-44: Spark Therapeutics Corporate Summary
Company Summary
Products
Tessa Therapeutics, Ltd.
- Table 10-45: Tessa Therapeutics Corporate Summary
Company Summary
Products
uniQure N.V.
- Table 10-46: UniQure Corporate Summary
Company Summary
Products
Vericel Corporation
- Table 10-47: Vericel Corporate Summary
Company Summary
Products
